IRVINE, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced it is proud to serve as a platinum sponsor of the 2014 Parkinson's Unity Walk in New York City's Central Park on Saturday, April 26. "We are excited to participate as a sponsor of this inspirational fundraising event that supports research into a cure for Parkinson's disease," stated Kimble Jenkins, MRI Interventions' President and CEO. "MRI Interventions is committed to developing technologies that expand treatment options for patients, such as our ClearPoint system, which enables 'asleep' deep brain stimulation surgery to treat symptoms of Parkinson's disease. Our goal is to improve the lives of people who have been dealt the incredible burden of a neurological disorder like Parkinson's, and we are happy to back the Unity Walk in its similar efforts." The Parkinson's Unity Walk (PUW), a grassroots organization, began in 1994 through the dedicated efforts of patients, families, support groups, and friends who were affected by Parkinson's disease. Their main goal was to raise awareness and funds for research to find a cure for Parkinson's. Over the last nineteen years, the Unity Walk has grown from 200 participants in the first event to over to 10,000 participants in the 2013 Walk. Donations from the Unity Walk have gone to support research for major U.S. Parkinson's foundations including American Parkinson Disease Association (APDA), National Parkinson Foundation, Inc. (NPF), Parkinson's Action Network (PAN), Parkinson's Disease Foundation (PDF), The Michael J. Fox Foundation for Parkinson's Research (MJFF), The Parkinson Alliance (PA) and The Parkinson's Institute and Clinical Center (PI). To join a team, make a donation or learn more about the Parkinson's Unity Walk, please visit www.unitywalk.org . About MRI Interventions, Inc. Founded in 1998, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared and CE-marked ClearPoint ® System is designed to enable a range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace ® System to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. For more information, please visit www.mriinterventions.com . Forward-Looking Statements Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Detailed information on factors that could affect MRI Interventions' actual results are described in MRI Interventions' filings with the Securities and Exchange Commission, including, without limitation, the annual report on Form 10-K filed on March 28, 2014. Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in MRI Interventions' expectations or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: MRI Interventions, Inc. David Carlson, CFO, 901-522-9300